The Hematopoietic Stem Cell Transplantation drugs in development market research report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hematopoietic Stem Cell Transplantation. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Hematopoietic Stem Cell Transplantation by 15 companies/universities/institutes. The top development phase for Hematopoietic Stem Cell Transplantation is preclinical with six drugs in that stage. The Hematopoietic Stem Cell Transplantation pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hematopoietic Stem Cell Transplantation pipeline products market are: Orca Biosystems, Omeros and Miyarisan Pharmaceutical.
The key targets in the Hematopoietic Stem Cell Transplantation pipeline products market include Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104), Sphingosine 1-Phosphate Receptor (S1PR), and Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA).
The key mechanisms of action in the Hematopoietic Stem Cell Transplantation pipeline product include Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104) Inhibitor with two drugs in Filing rejected/Withdrawn. The Hematopoietic Stem Cell Transplantation pipeline products include six routes of administration with the top ROA being Intravenous and seven key molecule types in the Hematopoietic Stem Cell Transplantation pipeline products market including Cell Therapy, and Small Molecule.
Hematopoietic Stem Cell Transplantation overview
Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. It may be autologous (the patient’s own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). It is most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia.
For a complete picture of Hematopoietic Stem Cell Transplantation’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
